Annals of Surgical Oncology最新文献

Background: The clinical value of incorporating lipid and inflammatory factors to predict long-term survival in patients with gastric cancer (GC) is unreported. This study aimed to investigate the clinical value of nomograms integrating the Circulating Lipid and Inflammation Risk Score (CLIRS) for predicting the long-term outcome of patients with GC.

Methods: A retrospective analysis included patients with GC who underwent radical resection at four tertiary medical centers. Patients were divided into training and validation cohorts, with least absolute shrinkage and selection operator regression selecting optimal lipid and inflammatory indicators related to GC prognosis. The CLIRS was developed from six indicators: lymphocyte, triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and apolipoprotein B.

Results: Overall, 2534 patients were studied, including 1910 in the training cohort and 624 in the validation cohort. The CLIRS was an independent risk factor for overall survival (OS; hazard ratio [HR] 1.529, 95% confidence interval [CI] 1.271-1.839; p < 0.001) and disease-free survival (DFS; HR 1.511, 95% CI 1.267-1.801; p < 0.001) in GC patients. The OS nomogram (area under the receiver operating characteristic curve 0.823 vs. 0.785; p < 0.05) and DFS nomogram (AUC 0.804 vs. 0.770; p < 0.05) based on the CLIRS outperformed pTNM stage. High-risk patients had earlier and more sustained recurrence, with higher rates of local, peritoneal, and distant recurrences (p < 0.05).

Conclusions: The CLIRS, combining circulating lipid and inflammatory factors, is an independent prognostic factor for patients with GC. Nomograms incorporating the CLIRS are superior to pTNM stage in predicting postoperative survival and recurrence in patients with GC.

Background: There is limited data regarding sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) for cN3b patients, who present with both axillary and ipsilateral internal mammary node involvement. We examined trends in the use of SLNB in cN3b patients and survival by axillary procedure for those with nodal pathologic complete response (nPCR).

Methods: Adult women with nonmetastatic cN3b invasive breast carcinoma between 2012 and 2021 were selected from the National Cancer Database. These patients were compared based on type of axillary surgery, specifically SLNB, SLNB with axillary lymph node dissection (ALND), and ALND alone. Kaplan-Meier analysis was used to compare overall survival.

Results: A total of 4,236 patients were included. In 2012, 8.5% of these patients underwent SLNB alone and 18.3% underwent SLNB+ALND. In 2021, this increased to 35.1% for SLNB alone and 23.0% for SLNB with subsequent ALND (p < 0.0001). For patients who received NAC, the rate of nPCR was overall found to be 24.9%. Overall survival of patients receiving SLNB or SLNB+ALND with nPCR was not statistically significantly different from the ALND only group with nPCR (p = 0.22 and 0.57, respectively).

Conclusions: There has been increasing use of the SLNB procedure for patients with cN3b breast cancer over the past decade. In patients with nPCR, SLNB was not associated with reduced survival. For well-selected cN3b patients with an excellent clinical response to NAC, including nPCR, axillary de-escalation strategies, such as SLNB with omission of completion axillary dissection, may be considered.

Introduction: There is a demand for intraoperative diagnostic support and image guidance in oncological surgery. Novel techniques can provide images similar to histopathological slides within a few minutes. Optical coherence tomography (OCT) and full-field OCT (FF-OCT) provide images with resolution greater than a hundred micrometers without the need for exogenous contrast agents or specimen staining. The aim of this systematic review was to assess the current clinical applications of OCT and dynamic cell imaging (DCI) in oncologic surgery, examining the translation challenges and proposing perspectives for improving future clinical applications.

Materials and methods: The study adhered to the PRISMA guidelines. PubMed, Google Scholar, and ClinicalTrials.gov were searched up to July 2024. Manuscripts reporting data on OCT and (D)-FF-OCT application in oncologic surgery were included in the qualitative analysis.

Results: Thirty-one studies met the inclusion criteria. Most were from the fields of dermatologic (25.8%) and breast cancer (29%) surgery, followed by prostate and bladder (9.6%), ovarian (9.6%), head and neck (6.4%), gastrointestinal (6.4%), hepato-biliary (3.2%), and general surgery (9.6%). The majority of articles focused on FF-OCT and DCI (80.6%). Compared with the gold standard of final pathology, the OCT sensitivity ranged between 66.7 and 94%, the specificity between 64 and 100%, and the accuracy between 73 and 96%.

Conclusions: The medical use of OCT has expanded from ophtalmology to other fields including gastroenterology and oncology and, with techniques such as FF-OCT and DCI, can enable rapid intraoperative diagnosis beyond classic histopathology.

Background: The association between tumor-infiltrating lymphocytes and tumor immunity has long been recognized. Among T-cell types, CD45RO-positive memory T cells (CD45RO⁺) are reported to correlate with survival in several cancer types, but clinical evidence is lacking in esophageal squamous cell carcinoma (ESCC).

Methods: In surgical specimens from 162 preoperatively untreated patients, immunohistochemistry for CD45RO was performed to evaluate the density of CD45RO⁺ in the tumor core (CT) and invasive margin (IM) using an auto-count method. Patients were classified into high- versus low-CD45RO⁺ groups based on CD45RO⁺ density in CT and IM separately and combined. The relationship between CD45RO⁺ density and clinicopathological factors, including prognosis, was evaluated.

Results: Average CD45RO⁺ density was 133/mm² in CT and 372/mm² in IM. No significant differences in clinicopathological factors according to high- versus low-CD45RO⁺ scores were identified. Using CT scores, the CD45RO⁺-high group had a better 5-year overall survival (OS) rate (77.2% vs. 54.7% CD45RO⁺-low, P = 0.0433), but OS rates did not differ statistically between the two groups by IM scores (75.7% vs. 50.3%, P = 0.0576). Using immunohistochemical scores for CT+IM, the survival difference was significant, with a 5-year OS rate of 73.7% for the CD45RO⁺-high group versus 46.3% for the CD45RO⁺-low group (P = 0.0141). Multivariate analysis identified CD45RO⁺ CT+IM density as an independent prognostic variable in OS (hazard ratio 2.27, 95% confidence interval 1.43-3.62, P = 0.0006).

Conclusions: Density of CD45RO⁺ expression in the CT and IM might be a predictor of long-term survival in ESCC.

Surgery is the only definitive treatment for primary hyperparathyroidism (PHPT). The surgical management of PHPT has evolved over the past several decades in response to the continually growing body of evidence supporting its effectiveness in both symptomatic and asymptomatic disease. As imaging modalities for localization, operative approach, and intraoperative adjuncts, such as intraoperative parathyroid hormone testing, have been optimized, careful evaluation of the timing of parathyroidectomy in relationship to the disease's natural history has been pursued to limit the detrimental end-organ effects of untreated PHPT. Herein, we review select studies examining key aspects of PHPT management fundamental to the practicing surgical oncologist and endocrine surgeon caring for patients with PHPT.

Introduction: The standard of care for gastric cancer in the United States involves perioperative chemotherapy. While most post-therapy pathologic staging results are concordant (i.e. ypT⁺N⁺ or ypT0N0), patients occasionally display discordant results, such as ypT0N1. Herein, we characterized the survival of patients with ypT0N1 staging to better determine their categorization within the American Joint committee on Cancer (AJCC) staging system.

Methods: Using the National Cancer Database (NCDB), we queried all patients diagnosed with gastric adenocarcinoma from 2004 to 2021 who received neoadjuvant chemotherapy. Patients were stratified by their ypTNM stage: (1) ypT0N0; (2) ypT+N0; (3) ypT+N1; and (4) ypT0N1. Multivariable Cox proportional hazard regression was used to assess 5- and 10-year survival between ypTNM stages.

Results: A total of 28,985 patients received neoadjuvant chemotherapy, of whom 2378 (8.2%) had ypT0N0, 9402 (32.4%) had ypT+N0, 5339 (18.4%) had ypT+N1, and 318 (1.1%) had ypT0N1 staging. Overall, patients had a median age of 64 years, with the majority being male (74.9%) or White (82.2%). Additionally, 50.2% received care from an academic center, and 53.3% received neoadjuvant chemotherapy and radiotherapy. On multivariable analysis, patients with ypT0N1 had a 105% higher risk for mortality within 5 years (adjusted hazards ratio [aHR] 2.05, 95% confidence interval [CI] 1.69-2.50) and 86% increased risk within 10 years (aHR 1.86, 95% CI 1.54-2.23) when compared with ypT0N0.

Conclusion: Patients with stage ypT0N1 disease have worse 5- and 10-year outcomes than those with node-negative disease. Thus, their survival pattern most closely matches patients with ypstage IIB and III disease.

Background: Gallbladder cancer is a rare disease with poor prognosis, for which surgical resection is considered the only curative treatment.¹ The widespread adoption of laparoscopic cholecystectomy for benign biliary diseases has led to an increased incidence of postoperatively diagnosed gallbladder cancer.^2-5 Several studies have proposed that tumors exceeding stage T2 require additional resection.^3,6,7 However, reoperation for postoperatively diagnosed gallbladder cancer is technically difficult due to inflammatory adhesion or fibrosis around the hepatoduodenal ligament and gallbladder bed.^8,9 For such reasons, there are limited evidence regarding the safety and feasibility of laparoscopic reoperation and no clear indications for when to perform minimally invasive surgery.

Methods: In this multimedia article, we present the laparoscopic reoperation techniques for postoperatively diagnosed gallbladder cancer. We focus specifically on various approaches to surgically manage the cystic duct stump, depending on the length of remnant stump, degree of surrounding fibrosis, and margin status.

Results: We represent three cases with different approaches. In the first case, a patient with a long remnant stump is managed with clip ligation and resection of the stump. Second, a patient with a short remnant stump and severe fibrosis is treated with stump excision and suture closure. Lastly, bile duct resection is performed for a patient with margin involvement during the initial operation.

Conclusions: Various technical options exist to approach the remnant cystic duct stump during laparoscopic reoperation for postoperatively diagnosed gallbladder cancer.

Background: Perioperative complication rates and in-hospital mortality after radical nephroureterectomy (RNU) in patients with a history of heart valve replacement are unknown.

Methods: Within the National Inpatient Sample (2000-2019), we identified non-metastatic upper urinary tract carcinoma patients treated with RNU according to the presence or absence of a history of heart valve replacement. Propensity score matching (1:10 ratio) and multivariable logistic regression as well as Poisson regression models were used.

Results: Of 15,423 RNU patients, 151 (1.0%) harbored heart valve replacement. This proportion increased over the study span from 0.5% to 1.4% (p = 0.02). Heart valve replacement patients were older (median 78 vs. 72 years; p < 0.001), more frequently male (73 vs. 60%; p = 0.002), and more frequently harbored a Charlson Comorbidity Index (CCI) ≥3 (36 vs. 27%; p = 0.002). After 1:10 propensity score matching for age, sex, and CCI, the patients exhibited higher rates of perioperative bleeding (7.4 vs. 2.4%; odds ratio [OR] 3.2; p < 0.001), blood transfusions (24.0 vs. 17.0%; OR 1.6; p = 0.02), and cardiac complications (24.0 vs. 14.0%; OR 2.1; p < 0.001). Conversely, heart valve replacement patients did not exhibit higher rates of critical care therapy (OR 1.06; p = 0.8), higher rates of in-hospital mortality (OR 0.8; p = 0.8), and longer length of stay (OR 1.4; p = 0.052) than their RNU counterparts without a history of heart valve replacement.

Conclusion: RNU patients with a history of heart valve replacement are at significantly increased risk of perioperative bleeding, blood transfusions, and cardiac complications; however, despite these increased risks, they neither exhibited higher critical care therapy rates or higher in-hospital mortality rates, nor did they require significantly longer hospital stay.